J Subst Abuse Treat. 2001 Dec;21(4):217-21.

Olanzapine treatment for patients with schizophrenia and substance abuse.

Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG.

Source

The Promedica Research Center, 3561 Habersham at Northlake, Suite J-200, Tucker, GA 30084, USA. promedica@aol.com

Abstract

The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders. Thirty patients who met DSM-IV criteria for schizophrenia or schizoaffective disorder as well as criteria for substance abuse or substance dependence, were treated in a 12-month prospective, open-label trial of olanzapine. Patients were evaluated with multiple efficacy and safety measures at baseline and then monthly thereafter. Statistically significant improvement was noted in psychopathology, levels of hope, and safety measures. Seventy percent (n = 21) of the patients achieved early full substance abuse remission at the end of the study period, while 30% (n = 9) achieved early partial substance abuse remission. Our results indicate that olanzapine treatment improved psychopathology, increased hopefulness, and reduced antipsychotic-associated side effects. The benefits observed with olanzapine treatment may contribute to the patients' substance abuse remission.

PMID:: 11777671; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Clinical Trial

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. [J Clin Psychiatry. 2002]
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP. J Clin Psychiatry. 2002 Oct; 63(10):931-5.
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. [Int Clin Psychopharmacol. 2003]
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
Lambert M, Holzbach R, Moritz S, Postel N, Krausz M, Naber D. Int Clin Psychopharmacol. 2003 Sep; 18(5):251-60.
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. [Clin Neuropharmacol. 2007]
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.
Gerra G, Di Petta G, D'Amore A, Iannotta P, Bardicchia F, Falorni F, Coacci A, Strepparola G, Campione G, Lucchini A, et al. Clin Neuropharmacol. 2007 May-Jun; 30(3):127-35.
Review [Antipsychotics in bipolar disorders]. [Encephale. 2004]
Review [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Encephale. 2004 Sep-Oct; 30(5):417-24.
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. [Encephale. 2005]
Review [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. Encephale. 2005 Mar-Apr; 31(2):235-46.

See reviews... See all...

Cited by 6 PubMed Central articles

Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. [Front Psychiatry. 2011]
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.
Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkallah E, Rompré PP, Bentaleb LA, Lipp O, Chiasson JP, Gendron A, et al. Front Psychiatry. 2011; 2:22. Epub 2011 May 13.
Review Substance abuse and schizophrenia: pharmacotherapeutic intervention. [J Subst Abuse Treat. 2008]
Review Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Green AI, Noordsy DL, Brunette MF, O'Keefe C. J Subst Abuse Treat. 2008 Jan; 34(1):61-71. Epub 2007 Jun 15.
Review Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. [J Psychiatr Pract. 2005]
Review Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.
Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. J Psychiatr Pract. 2005 Sep; 11(5):315-39.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Olanzapine treatment for patients with schizophrenia and substance abuse.
Olanzapine treatment for patients with schizophrenia and substance abuse.
J Subst Abuse Treat. 2001 Dec ;21(4):217-21.

PubMed
Feline dirofilariosis: antibody response to antigenic fractions containing speci...
Feline dirofilariosis: antibody response to antigenic fractions containing specific 20 to 30 kDa polypeptides from the adult Dirofilaria immitis somatic antigen.
Vet Parasitol. 2002 Feb 4 ;103(4):341-53.

PubMed
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of ...
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
Obstet Gynecol. 2002 Jan ;99(1):135-44.

PubMed
Vaginal bleeding patterns among rural highland Bolivian women: relationship to f...
Vaginal bleeding patterns among rural highland Bolivian women: relationship to fecundity and fetal loss.
Contraception. 2001 Nov ;64(5):319-25.

PubMed
Airway fire during tracheostomy: prevention strategies for surgeons and anaesthe...
Airway fire during tracheostomy: prevention strategies for surgeons and anaesthetists.
Ann R Coll Surg Engl. 2001 Nov ;83(6):376-80.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: